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Abstract
Background: The perioperative use of antithrombotic therapy is associated with increased bleeding risk after
cardiac implantable electronic device (CIED) implantation. Topical application of tranexamic acid (TXA) is effective in
reducing bleeding complications after various surgical operations. However, there is no information regarding local
TXA application during CIED procedures. The purpose of our study was to evaluate bleeding complications rates
during CIED implantation with and without topical TXA use in patients receiving antithrombotic treatment.
Methods: We conducted a retrospective analysis of consecutive patients undergoing CIED implantation while
receiving warfarin or dual antiplatelet (DAPT) or warfarin plus DAPT treatment. Study population was classified in
two groups according to presence or absence of topical TXA use during CIED implantation. Pocket hematoma (PH),
major bleeding complications (MBC) and thromboembolic events occuring within 90 days were compared.
Results: A total of 135 consecutive patients were identified and included in the analysis. The mean age was
60 ± 11 years old. Topical TXA application during implantation was reported in 52 patients (TXA group). The
remaining 83 patients were assigned to the control group. PH occurred in 7.7 % patients in the TXA group and
26.5 % patients in the control group (P = 0.013). The MBC was reported in 5.8 % patients in the TXA and 20.5 %
patients in control group (P = 0.024). Univariate logistic regression analysis identified age, history of recent stent
implantation, periprocedural spironolactone use, periprocedural warfarin use, perioperative warfarin plus DAPT use,
cardiac resynchronization therapy, and topical TXA application during CIED implantation as predicting factors of PH.
Multivariate analysis showed that perioperative warfarin plus DAPT use (OR = 10.874, 95 % CI: 2.496–47.365, P = 0.001)
and topical TXA application during CIED procedure (OR = 0.059, 95 % CI: 0.012–0.300, P = 0.001) were independent
predictors of PH. Perioperative warfarin plus DAPT use and topical TXA application were also found to be independent
predictors of MBC in multivariate analyses. No thromboembolic complications was recorded in the study group.
Conclusion: The present study demonstrated that the topical TXA application during CIED implantation is associated
with reduced PH and MBC in patients with high bleeding risk.
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Background
The number of cardiac implantable electronic device
(CIED) implantation has increased considerably in the last
decade [1] and has been continuing to increase parallel to
expanded indications in the most recent guidelines [2, 3].
As a result, numerous patients have undergone CIED im-
plantation while receiving antithrombotic therapy for few
years [4]. Perioperative management of these patients is
very challenging with a high risk of bleeding [5]. Pocket
hematoma is relatively common complication (reported
rates between 2 % and 5 %) [6–8], and dual antiplatelet
therapy (DAPT) increases the risk fivefold [6], and fur-
thermore rate of bleeding complication can be as high as
40 % with triple therapy [9].
In the presence of moderate or high thromboembolic
risk, physicians usually accept the risk of bleeding and
continue the antithrombotic therapy perioperatively. It is
clearly known that postoperative bleeding complications
constitutes not only financial but also significant medical
burden. Several experience based strategies are available
to reduce the incidence of pocket hematoma: meticulous
use of cautery, tamponade of pocket with gauze during
lead implantation, wound drainage, pressure bandage
and hemostatic use. Also, some hemostatic agents were
found to be ineffective in preventing pocket hematoma,
besides increasing the risk of pocket infection [10]. Also,
these agents are not available in every clinic, need time
to be prepared and all increases the cost.
Tranexamic acid (TXA) is a synthetic antifibrinolytic
agent that binds to the lysine binding site of plasmino-
gen and blocks its binding to fibrin surface [11]. Topical
application of TXA is effective in reducing bleeding
complications after various surgical operations [11].
However, there is no information regarding local TXA
application during CIED procedures. The purpose of our
study was to evaluate bleeding complications rates dur-
ing CIED implantation with and without topical TXA
use in patients receiving antithrombotic treatment.
Methods
Study cohort
We conducted a retrospective analysis of consecutive pa-
tients undergoing CIED implantation while receiving anti-
thrombotic therapy, namely, warfarin or warfarin plus
DAPT or DAPT. Between June 2011 and February 2015,
989 consecutive patients who underwent CIED procedures
at Cumhuriyet University Hospital, Sivas, Turkey and Cag
Hospital, Ankara, Turkey were considered. At index pro-
cedure, a total of 319 patients were on chronic background
therapy with warfarin or warfarin plus DAPT or DAPT.
Indication of DAPT consisting of combination of acetylsali-
cylic acid and clopidogrel was recent stent implantation
(within 3–12 months) in all patients receiving DAPT.
Exclusion criteria were: use of other antiplatelets (e.g.
prasugrel, ticagrelor, ticlopidine), heparin bridging strategy,
interrupted antiplatelet therapy more than 2 days before
the procedure, unknown international normalization ratio
(INR) or INR values inconsistent with target range at the
day of procedure, periprocedural bleeding not related to
CIED procedure (eg, gastrointestinal bleeding, hematuria,
etc.), lead extraction with laser or mechanical dilator (As a
protocol, all antithrombotic drugs have been discontinued
at least 7 days prior to this procedure in both clinics). Inclu-
sion criteria were one of the below strategies for periopera-
tive antithrombotic management:
Uninterrupted warfarin; Warfarin therapy was
continued to maintain INR in the therapeutic range
(2.0–3.5), but dosage of warfarin was adjusted to
maintain INR between 1.9 and 2.5 at the day of
procedure.
Uninterrupted warfarin plus DAPT; In addition to
uninterrupted warfarin strategy, aspirin and/or
clopidogrel was continued perioperatively without dose
skipping more than 2 days before the procedure.
Uninterrupted DAPT; Aspirin and/or clopidogrel was
continued perioperatively without dose skipping more
than 2 days before the procedure.
Hospital records were reviewed to determine medica-
tions at admission and during perioperative period. Pa-
tients were grouped according to antithrombotic
medications at admission (Fig. 1, top and bottom). A
protocol for topical utilization of TXA during CIED im-
plantations was proposed for the high risk patients at
Cumhuriyet University by August 2013 up on several
discussions of Heart Team and advised to Cag Hospital
as well and the protocol has been routinely used in both
hospital since August 2013. Hence, TXA group consisted
of patients who underwent CIED procedure after August
2013 (between August 2013 and February 2015) and the
control group consisted of patients who underwent
CIED procedure before August 2013 (between June
2011- July 2013). The study was approved by the Ethics
Committee of the Faculty of Medicine, Firat University
(reference number: 201602/06) and conducted in
accordance with the Helsinki Declaration.
Definitions
Procedure related bleeding complications was recorded
as pocket hematoma and major bleeding complications
(MBC). Pocket hematoma (PH) was defined as swelling
and a painful mass with ecchymosis formation extending
the margin of generators.
MBC defined as any CIED procedure related bleeding
leading to red blood cell (RBC) transfusion, surgical
intervention for pocket evacuation or revision, pericar-
dial effusion, hemothorax, or life-threatening bleed [6].
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If a patient experienced multiple MBC, the clinical time
course was reviewed to ensure that complications
counted were distinctly separate events related to the
CIED procedure.
Thromboembolic events were defined as transient is-
chemic attack, stroke, myocardial infarction, systemic
embolism, mechanical valve thrombosis, deep vein
thrombosis, and pulmonary embolism.
Implantation techniques
All procedures were performed by experienced cardiolo-
gists, blinded to study plan. All of the implanting physi-
cians had an experience of at least 150 operations per
annum with a similar experience in years (>3 years). All
the patients were administered intravenous prophylactic
antibiotics (mostly cefazolin, a first generation cephalo-
sporin) per hospital protocol. After administration of local
anesthesia (lidocaine or prilocaine hydrochloride), an inci-
sion was made in the prepectoral region and a subcutane-
ous or submuscular pocket was formed according to
device and subcutaneous tissue features of the patient.
Electro cautery ± ligatures were routinely used to obtain
complete surgical hemostasis. All the leads were im-
planted via sublavian/axillary venous puncture (one punc-
ture per lead) or cephalic cut-down. Right ventricular
leads were usually targeted to the interventricular septum
Fig. 1 Flow chart of the patients who participated in the study as postive control (top) or tranexamic acid (bottom) group and the assignment of
the patients to medication subgroups on the basis of medications taken during the periprocedure period is displayed. INR values at the day of
procedure were used in exclusion boxes. DAPT = dual antiplatelet treatment
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of right ventricle. The left ventricular leads were inserted
through the coronary sinus. After lead measurements with
analyzer, leads were sutured using nonabsorbable silk
sutures at the venous site. Generators were placed in pre-
formed pocket and were sutured using nonabsorbable silk
sutures. The incision was closed in three layers using
absorbable sutures, and a sterile pressure dressing was ap-
plied. Implantation technique were same for all patients
except additional local TXA application in TXA group.
Utilization of topical transexamic acid during implantation
According to our protocol, after pocket formation and
complete surgical hemostasis with electrocoutery ± surgi-
cal ligation, pocket and the incision sites were washed
with 500 mg/5 ml TXA without removing with suction.
Then, a standard gauze soaked in 5 ml solution containing
500 mg of TXA was placed in the prepared pocket, and
steady and direct pressure by using the palm of one hand
was applied on the gauze from the skin for 1–3 min. The
gauze was left in the pocket throughout the procedure
and was removed from the pocket before the device place-
ment in the pocket. Lastly, pocket and incision sites were
washed with 500 mg/5 ml TXA just before incision clos-
ure without removing with suction.
All the cardiologists performing CIED implantation
have known the topical TXA protocol well (experience
of at least 15 implantations with TXA). All details about
the procedure was routinely documented by the attend-
ing cardiologist and it was recorded both in computer
based system and patient’s CIED file.
Postoperative care and data collection
A pressure dressing was applied to the wound for 24–36 h.
A chest X-ray was obtained after the procedure. Intraven-
ous antibiotics and oral or iv pain medications (mostly
asetaminofen) were given for 1–3 days. All cardiac medica-
tions were continued. Patients were discharged at third day
after the procedure. All patients were evaluated at discharge
and 7, 15, 30 and 90 days after the procedure to access
wound and suture integrity, pocket hematoma, thrombo-
embolic events, CIED functions, device infection, or other
problems in outpatient outpatient cardiology clinic and
findings were recorded in patient’s CIED file.
Data were retrospectively collected from patient’s file,
medical observations and computer based database sys-
tem. In addition to usual patient characteristics, the fol-
lowing information were collected: all medications,
technical surgical details and laboratory data.
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation or median (min-max) in the presence of ab-
normal distribution, and categorical variables as percent-
ages. Comparisons between groups of patients were
made by use of a χ2 test for categorical variables, inde-
pendent samples t test for normally distributed continu-
ous variables, and Mann-Whitney U test when the
distribution was skewed. We used univariate logistic re-
gression analysis to quantify the association of variables
with occurrence major bleeding and PH. Age, presence
of LV thrombus, history of recent stent implantation,
spironolactone use, periprocedural warfarin use, peripro-
cedural warfarin plus DAPT use, ICD device implant-
ation, three lead implantation, and topical TXA use
during CIED implantation were entered into the multi-
variate logistic regression model for determining the in-
dependent predictors of PH. Hypertension, history of
recent stent implantation, spironolactone use, periproce-
dural warfarin use, periprocedural warfarin plus DAPT
use, and topical TXA use during implantation were en-
tered into the multivariate logistic regression model in
order to determine the independent predictors of MBC.
All statistical procedures were performed using SPSS
software version 14.0 (SPSS Inc., Chicago, IL). A p value
of 0.05 was considered as statistically significant.
Results
Study population
A total of 135 consecutive patients were identified and in-
cluded in the present analysis. Topical TXA use was noted
in 52 patients during implantation the remaining 83 pa-
tients were assigned to be as control group that included
traditional routine precautions in these high risk patients.
The mean age was 60 ± 11 years with 81 (60 %) males.
Baseline characteristics of the study population are pre-
sented in Table 1 and all variables were statistically similar
between the groups. Procedure related characteristics of the
study population are presented in Table 2. There was no
difference between the groups according to these variables.
Procedure related complications
Procedure related complications are presented in Table 3.
A total of 28 MBC events (reoperation, RBC transfusion,
hemothorax, pericardial effusion, and life-threatening
bleed) were reported in 20 patients (14.8 %) in the study
population (Table 3). MBC occurred in 3 patients (5.8 %)
in the TXA group and in 17 patients (20.5 %) in the con-
trol group (P = 0.024) (Table 3). Total counted event rates
of reoperation and RBC transfusion were statistically
higher in control group (9.6 % vs 0.0 %, P = 0.023 and
15.7 % vs 3.8 %, P = 0.047, respectively). PH occurred in 4
patients (7.7 %) in the TXA group and 22 patients
(26.5 %) in the control group (P = 0.013). The detailed
characteristics of patients with pocket hematoma and
MBC are summarized in Additional file 1: Table S1.
One pocket related infections (after hematoma evacu-
ation procedure) requiring full system extraction was re-
ported in control group. Pneumothorax was occurred in
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2 patients (one in control group and 1 in TXA group,
and chest tube drainage was required for both). One pa-
tient (78 years old male patient receiving periprocedural
DAPT) died after implantation because of complicating
hemathorax and large pericardial effusion in the control
group. Two patients had pericardial effusion which re-
quired pericardiosynthesis. No thromboembolic compli-
cations were occurred in the study group perioperatively
and 90 days after the procedure.
Predictors of pocket hematoma
Baseline characteristics of the study population according
to presence and absence of PH are presented in Table 4.
Mean age was statistically higher in PH positive group (n =
26) compared to PH negative group (n = 109) (64 ± 12 vs
59 ± 11, P = 0.037). More patients had history of recent
stent implantation in PH positive group (88.5 % vs 36.7 %,
P < 0.001). Periprocedural warfarin plus DAPTand spirono-
lactone use were higher in PH positive group compared to
PH negative (57.7 % vs 10.1 %, P < 0.001 and 73.1 % vs
44.0 %, P = 0.015, respectively). Periprocedural warfarin use
was higher in PH negative group (62.4 % vs 15.4 %, P <
0.001) (Table 4).
Procedure related characteristics of the study popula-
tion according to PH are presented in Table 5. More
ICD devices were implanted in PH positive group com-
pared to PH negative group (96.2 % vs 78.9 %, P =
0.045). The topical TXA use during CIED implantation
was higher in MBC negative group compared to MBC
positive group (44.0 % vs 15.4 %, P = 0.013).
Results of univariate and multivariate analyses for predic-
tion of PH occurrence are presented in Table 6. In the
study group, univariate analyses identified seven predictors
of PH: age (OR = 1.043, 95 % CI: 1.002–1.085, P = 0.040),
history of recent stent implantation (OR = 13.225, 95 % CI:
3.734–46.839, P < 0.001), periprocedural spironolactone use
(OR = 3.449, 95 % CI: 1.340–8.879, P = 0.010), periproce-
dural warfarin use (OR = 0.110, 95 % CI: 0.035–0.341, P <
Table 1 Baseline characteristics of study population
Variables All patients (n = 135) Tranexamic acid (n = 52) Control (n = 83) P-value
Age (years) 60 ± 11 62 ± 10 59 ± 11 0.101
Male, n (%) 81 (60) 32 (61.5) 46 (59) 0.773
Body mass index (kg/m2) 25.4 ± 4.6 24.8 ± 4.0 25.8 ± 5.0 0.215
Smoking, n (%) 22 (16.3) 9 (17.3) 13 (15.7) 0.990
Hypertension, n (%) 74 (54.8) 29 (55.8) 45 (54.2) 0.860
Diabetes mellitus, n (%) 46 (34.1) 17 (32.7) 29 (34.9) 0.789
Previous CABG, n (%) 43 (31.9) 18 (34.6) 25 (30.1) 0.585
Ejection fraction, % 34 (20–55) 34 (20–55) 34 (20–55) 0.910
COPD, n (%) 19 (14.1) 9 (17.3) 10 (12.0) 0.548
Hemoglobin, g/dL 12.8 (9.5–15.1) 12.9 (9.5–14.5) 12.8 (9.5–15.1) 0.989
Platelet count, K/mm3 244 ± 57 240 ± 56 247 ± 58 0.476
BUN, mg/dL 30.6 (22–45) 30.6 (25–43) 30.6 (22–45) 0.926
Creatinine, mg/dL 1.1 ± 0.4 1.0 ± 0.4 1.1 ± 0.4 0.447
Atrial fibrillation, n (%) 43 (31.9) 22 (42.3) 21 (25.3) 0.039
Metallic prosthetic valve, n (%) 54 (40.0) 20 (38.5) 34 (41.0) 0.773
LV thrombus, n (%) 9 (6.7) 6 (11.5) 3 (3.6) 0.087
Recent stent implantation, n (%) 63 (46.7) 27 (51.9) 36 (43.4) 0.333
Medications
ACEI/ARB, n (%) 95 (70.4) 36 (69.2) 59 (71.1) 0.818
Beta blocker, n (%) 112 (83) 43 (82.7) 69 (83.1) 1.0
Diuretic, n (%) 99 (73.3) 37 (71.2) 62 (74.7) 0.800
Spironolactone, n (%) 67 (49.6) 25 (48.1) 42 (50.6) 0.775
Statin, n (%) 62 (45.9) 24 (46.2) 38 (45.8) 0.966
Warfarin, n (%) 72 (53.3) 25 (48.1) 47 (56.6) 0,333
DAPT, n (%) 37 (27.4) 16 (30.8) 21 (25.3) 0.621
Warfarin plus DAPT, n (%) 26 (19.3) 11 (21.2) 15 (18.3) 0.828
ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, BUN blood urea nitrogen, CABG coronary artery bypass graft, COPD chronic
obstructive pulmonary disease, DAPT dual antiplatelet therapy, LV left ventricular
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0.001), perioperative warfarin plus DAPT use (OR = 12.149,
95 % CI: 4.483–32.920, P < 0.001), three lead implantation
during procedure (OR = 2.406, 95 % CI: 1.006–5.757, P =
0.049), and topical TXA application during CIED implant-
ation (OR 0.231, 95 % CI: 0.075–0.716, P = 0.011). Multi-
variate analysis of factors with P < 0.1 in univariate analysis
showed that perioperative warfarin plus DAPT use (OR =
10.874, 95 % CI: 2.496–47.365, P = 0.001) and topical TXA
application during CIED procedure (OR = 0.059, 95 % CI:
0.012–0.300, P = 0.001) were independent predictors of
MBC.
Predictors of major bleeding complications
In the study group, there were 20 patients with MBC
(MBC positive group) and 115 without MBC (MBC nega-
tive group). Baseline characteristics of the study population
according to major bleeding complications are presented in
Additional file 1: Table S2. More patients had history of
recent stent implantation in MBC positive group (80.0 % vs
40.9 %, P = 0.003). Periprocedural warfarin plus DAPT use
was higher in MBC positive group compared to MBC
negative (50.0 % vs 13.9 %, P = 0.001). Periprocedural war-
farin use was higher in MBC negative group (59.1 % vs
20.0 %, P = 0.003) (Additional file 1: Table S2).
Procedure related characteristics of the study popu-
lation according to MBC are presented in Additional
file 1: Table S3. The topical TXA use during CIED im-
plantation was higher in MBC negative group compared
to MBC positive group (42.6 % vs 15.0 %, P = 0.036).
Results of univariate and multivariate analyses for predic-
tion of MBC occurrence are presented in Additional file 1:
Table S4. In the study group, univariate analyses identified
four predictors of MBC: history of recent stent implant-
ation (OR = 5.787, 95 % CI: 1.820–18.406, P = 0.003), peri-
procedural warfarin use (OR = 0.173, 95 % CI: 0.054–0.550,
P = 0.003), perioperative warfarin plus DAPT use (OR =
Table 3 Procedure related complications
Complications All patients (n = 135) Tranexamic acid (n = 52) Control (n = 83) P-value
Major bleeding complications, n (%) 20 (14.8) 3 (5.8) 17 (20.5) 0.024
Reoperationa, n (%) 8 (5.9) 0 (0.0) 8 (9.6) 0.023
RBC transfusiona, n (%) 15 (11.1) 2 (3.8) 13 (15.7) 0.047
Hemothoraxa, n (%) 1 (0.7) 0 (0.0) 1 (1.2) 1.0
Pericardial effusiona, n (%) 3 (2.2) 1 (1.9) 2 (2.4) 1.0
Life-threatening bleeda, n (%) 1 (0.7) 0 (0.0) 1 (1.2) 1.0
Pocket hematoma, n (%) 26 (19.3) 4 (7.7) 22 (26.5) 0.013
Pocket related infection, n (%) 1 (0.7) 0 (0.0) 1 (1.2) 1.0
Pneumothorax, n (%) 2 (1.4) 1 (1.9) 1 (1.2) 1.0
RBC red blood cells. aCounted events were presented (If a patient experienced multiple major bleeding complications, the clinical time course was reviewed to
ensure that complications counted were distinctly separate events related to the procedure)
Table 2 Procedure related characteristics between the tranexamic acid and control groups
Characteristic All patients (n = 135) Tranexamic acid (n = 52) Control (n = 83) P-value
INR at the day of implanta 2.1 (1.9–2.5) 2.1(1.9–2.5) 2.1(1.9–2.5) 0.932
Generator exchange and/or pocket revision, n (%) 14 (10.4) 5 (9.6) 9 (10.8) 0.968
New implantation, n (%) 101 (74.8) 39 (75.0) 62 (74.7) 1.0
Upgrade and/or lead revision, n (%) 20 (14.8) 8 (15.4) 12 (14.5) 1.0
Pacemaker, n (%) 24 (17.8) 9 (17.3) 15 (18.1) 1.0
ICD, n (%) 111 (83) 43 (82.7) 68 (81.9)
Number of leads implanted
One, n (%) 26 (19.3) 12 (23.1) 14 (16.9) 0.505
Two, n (%) 50 (37.0) 18 (34.6) 32 (38.6) 0.645
Three, n (%) 45 (33.3) 17 (32.7) 28 (33.7) 0.900
Submuscular pocket, n (%) 5 (3.7) 2 (3.8) 3 (3.6) 1.0
Venous route other than subclavian
Axillary, n (%) 12 (8.9) 4 (7.7) 8 (9.6) 0.767
Cephalic, n (%) 7 (5.2) 3 (5.8) 4 (4.8) 1.0
DAPT dual antiplatelet therapy, ICD implantable cardioverter defibrillator, INR international normalized ratio
aThe median INR level of patients with warfarin continuation strategy
Beton et al. BMC Cardiovascular Disorders  (2016) 16:73 Page 6 of 10
6.187, 95 % CI: 2.224–17.216, P < 0.001), and topical TXA
application during CIED implantation (OR 0.238, 95 % CI:
0.066–0.856, P = 0.028). Multivariate analysis of factors with
P < 0.1 in univariate analysis showed that perioperative war-
farin plus DAPT use (OR = 8.144, 95 % CI: 2.589–25.618,
P < 0.001) and topical TXA application during CIED pro-
cedure (OR = 0.170, 95 % CI: 0.042–0.690, P = 0.013) were
independent predictors of MBC.
Discussion
The present study retrospectively investigated the effect of
additional topical TXA use during CIED procedure on PH
and MBC in a population with uninterrupted antithrom-
botic therapy strategy. The overall rates of PH and MBC
were 19.3 % and 14.8 %, respectively. The frequencies of
PH and MBC were significantly higher (3.4-fold and 3.5-
fold, respectively) in the control group compared to TXA
group. The counted event rates of reoperation and RBC
transfusion requirements were lower in TXA group. In
multivariate analysis, warfarin plus DAPT was found to be
an independent predictor of increased risk of PH and
MBC, whereas, topical TXA application during CIED was
found to be an independent predictor of decreased risk
PH and MBC.
Expanding CIED implantation indications are mainly
belonging to implantable cardioverter defibrillators
(ICD) and mostly includes patients with ischemic heart
disease [2, 3]. Some of those patients have recently
undergone coronary stent implantation. Following cor-
onary intervention the need for DAPT usually is tempor-
ally, the duration of therapy mainly depending on the
type of the stent (drug eluting or bare) [5]. Shortening
the initially recommended time period of DAPT is
highly discouraged due to high risk of stent thrombosis
[5]. Furthermore, some ICD implants should not be
postponed because of a potential risk of sudden cardiac
death. However, it is well known that bleeding complica-
tions occurs more frequently in patients receiving ICD
Table 4 Baseline characteristics according to pocket hematoma
Variables PH positive group (n = 26) PH negative group (n = 109) P-value
Age 64 ± 12 59 ± 11 0.037
Male, n (%) 14 (53.8) 67 (61.5) 0.624
Body mass index (kg/m2) 26.1 ± 5.7 25.3 ± 4.3 0.396
Smoking, n (%) 3 (11.5) 19 (17.4) 0.567
Hypertension, n (%) 18 (69.2) 56 (51.4) 0.154
Diabetes mellitus, n (%) 7 (26.9) 39 (35.8) 0.531
Previous CABG, n (%) 9 (34.6) 34 (31.2) 0.918
Ejection fraction, % 32 (25–55) 34 (20–55) 0.210
COPD, n (%) 3 (11.5) 16 (14.7) 1.0
Hemoglobin, g/dL 13.2 (10.8–15.1) 12.8 (9.5–14.5) 0.946
Platelet count, K/mm3 239 ± 69 246 ± 55 0.630
BUN, mg/dL 30.2 (25–39) 31.6 (22–45) 0.975
Creatinine, mg/dL 1.0 ± 0.4 1.1 ± 0.4 0.614
Atrial fibrillation, n (%) 10 (38.5) 33 (30.3) 0.568
Metallic prosthetic valve, n (%) 11 (42.3) 43 (39.4) 0.964
LV thrombus, n (%) 4 (15.4) 5 (4.6) 0.069
Recent stent implantation, n (%) 23 (88.5) 40 (36.7) <0.001
Medications
ACEI/ARB, n (%) 22 (84.6) 73 (67.0) 0.126
Beta blocker, n (%) 24 (92.3) 88 (80.7) 0.245
Diuretic, n (%) 21 (80.8) 78 (71.6) 0.479
Spironolactone, n (%) 19 (73.1) 48 (44.0) 0.015
Statin, n (%) 13 (50.0) 49 (45.0) 0.807
Warfarin, n (%) 4 (15.4) 68 (62.4) <0.001
DAPT, n (%) 7 (26.9) 30 (27.5) 1.0
Warfarin plus DAPT, n (%) 15 (57.7) 11 (10.1) <0.001
ACEI angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, BUN blood urea nitrogen, CABG coronary artery bypass graft, COPD chronic
obstructive pulmonary disease, DAPT dual antiplatelet therapy, LV left ventricular, PH pocket hematoma
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than those receiving PMs. [12] In the present study,
83 % of the devices were ICD and 46.7 % of the patients
had recent stent implantation.
BRUISE Control trial reported that the incidence of
hematoma is 3.5 % in patients with perioperative strat-
egy of uninterrupted warfarin group [13]. On the other
hand, in the FinPAC trial, the risk of hematoma was
similar in patients on aspirin (5.5 %) and warfarin
(5.6 %), but 0.9 % in patients with no antithrombotic
therapy [14]. The presence of wide variability among re-
ported incidence of pocket hematoma and bleeding
complications in the numerous published studies is ac-
cording to different criterias used. But, bleeding compli-
cations which require serious interventions such as
drainage (pocket, pericardial or pleural) or transfusion
are the only practically important ones. So, both PH and
MBC criterias were used for this study in coherent with
expectations about practical issues.
In the present study, periprocedural antithrombotic
treatment strategy was uninterrupted warfarin 53.3 % of
the patients, uninterrupted DAPT in 27.4 % of the pa-
tients, and uninterrupted warfarin plus DAPT (triple
therapy) in 19.3 % of the patients. Despite the high rates
of periprocedural antiplatelet therapy with warfarin and
ICD implantation, PH and MBC rates were relatively
low in TXA group. These findings may be attributed to
the topical TXA usage. According to a recent systemic re-
view, there is reliable evidence that topical application of
TXA reduces bleeding and blood transfusion in surgical
patients [11]. Although bleeding from CIED surgical sites
is usually controllable, there may be significant blood loss.
The topical administration of TXA intraoperatively can
Table 6 Univariate and multivariate predictors of pocket hematoma
Univariate Multivariate
Variables OR 95 % CI P-value OR 95 % CI P-value
Age 1.043 1.002–1.085 0.040
Presence of LV thrombus 3.782 0.939–15.228 0.061
History of recent stent implantation 13.225 3.734–46.839 <0.001
Spironolactone use 3.449 1.340–8.879 0.010
Periprocedural warfarin use 0.110 0.035–0.341 <0.001
Periprocedural warfarin plus DAPT use 12.149 4.483–32.920 <0.001 10.874 2.496–47.365 0.001
ICD device 6.686 0.860–51.991 0.069
Three lead implantation 2.406 1.006–5.757 0.049
Topical TXA use during CIED implantation 0.231 0.075–0.716 0.011 0.059 0.012–0.300 0.001
CI confidence interval, CIED cardiac electronic device implantation, DAPT dual antiplatelet therapy, ICD implantable cardioverter defibrillator, LV left ventricular,
MBC major bleeding complications, PH pocket hematoma, TXA tranexamic acid
Table 5 Procedure related characteristics according to pocket hematoma
Characteristics PH positive group (n = 26) PH negative group (n = 109) P-value
INR at the day of implanta 2.1 (2.0–2.5) 2.0 (1.9–2.5) 0.122
Generator exchange and/or pocket revision, n (%) 3 (11.5) 11 (10.1) 1.0
New implantation, n (%) 19 (73.1) 82 (75.2) 1.0
Upgrade and/or lead revision, n (%) 4 (15.4) 16 (14.7) 1.0
Pacemaker, n (%) 1 (3.8) 23 (21.1) 0.045
ICD, n (%) 25 (96.2) 86 (78.9)
Number of leads implanted
One, n (%) 2 (7.7) 24 (22.0) 0.165
Two, n (%) 8 (30.8) 42 (38.5) 0.610
Three, n (%) 13 (50.0) 32 (29.4) 0.076
Submuscular pocket, n (%) 1 (3.8) 4 (3.7) 1.0
Venous route other than subclavian
Axillary, n (%) 3 (11.5) 9 (8.3) 0.700
Cephalic, n (%) 2 (7.7) 5 (4.6) 0.620
Local tranexamic acid use 4 (15.4) 48 (44.0) 0.013
DAPT dual antiplatelet therapy, ICD implantable cardioverter defibrillator, INR international normalized ratio, PH Pocket hematoma. a The median INR level of
patients with warfarin continuation strategy
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directly target the source of bleeding and may stabilize the
multiple micro-clots that form within the wound contain-
ing high capillary density [11, 15].
Following the surgical trauma, clotting cascade is acti-
vated to produce a fibrin-based clot at the location of vas-
cular injury. Fibrinolysis begins soon after as a normal
homeostatic response to restore vascular patency and to
prevent positive feedback from causing clot activation
throughout the vascular compartment [15, 16]. However,
in the first hour after severe injury, hyperfibrinolysis can
occur which can lead to further bleeding, and TXA acts to
block this [15, 16]. Topical TXA may be more beneficial
especially in the presence antithrombotic therapy, when
capillary or venous ooze is more pronounced [17, 18]. In
addition, TXA may have positive impact on platelet func-
tions by inhibiting the conversion of plasminogen to plas-
min which impairs platelet functions [18].
In the past decade, some hemostatic agents were studied
in preventing pocket hematoma. A fibrin selant prior to
wound closure was shown to be effective in reducing the
number of pocket hematomas regardless of the anticoagu-
lation strategy used, but it may be associated with an in-
creased cost, viral transmission, allergic reactions to bovine
proteins or infections [19]. Recently, topical application of a
hemostat containing mixture of thrombin and collagen was
studied in patients on anticoagulants and/or antiplatelets
[10]. However, it was found that this hemostat does not de-
crease the frequency of clinically relevant pocket hemato-
mas, but increase the rate of pocket infections [10]. In the
present study, no allergic reaction was recorded. Also, no
pocket infection was observed in topical TXA group during
follow-up period. The low cost of the TXA was considered
as an additional advantage in comparison with other
hemostatic agents.
Similar to other studies, the present study found that
history of recent stent implantation and triple therapy
is associated with PH and MBC. Relationship of history
of recent stent implantation with PH and MBC could
be clearly attributed to DAPT usage in these pateints.
Because, patients with recent stent implantation were
on DAPT ± warfarin therapy in the present study
population. In univariate analyses, presence of left ven-
tricular (LV) thrombus was found to be related to in-
creased PH risk. In the present study, all patients with
LV thombus had previous history of anterior myocar-
dial infraction and recent stent implantation, and
thereby they had periprocedural uninterrupted war-
farin plus DAPT strategy which was found to be inde-
pendently related with PH complication. Additionally,
spironolactone use and three lead implantation (which
implies cardiac resynchronization therapy) during the
procedure were found to be related with increased risk
of PH in univariate analyses. More ICDs (especially
cardiac resynchronization therapy-defibrillator [CRT-
D]) were implanted in PH positive group, so the rate of
spironolactone use was higher in PH positive group.
Twenty (76.9 %) of the patients with PH had CRT-D im-
plantation procedure (13 new implantation, 4 upgrade
and/or lead revision, and 3 generator replacement)
(Additional file 1: Table S1). This finding was consistent
with other studies. In a recent review, it was stated that
rates of PH is around 2.5 % in ICD implantations, >3 %
in case of CRT-D or cardiac resynchronization
therapy-pacemaker (CRT-P) implantation, up to 4.2 %
in case of upgrading of a previous implant to CRT-P/
CRT-D, and 4.3 % in case of surgical revision of the im-
plant with repositioning due to dislocation or place-
ment of a new lead [20].
To our knowledge, this is the first study to demon-
strate that topical TXA use was associated with lower
PH and MBC rates during CIED procedures of patients
with uninterrupted antithrombotic therapy.
Limitations
Several limitations of this study should be acknowledged.
Firstly, it was a retrospective anaylsis which is suscep-
tible to bias in data selection. Secondly, sample size of
our study was relatively small, hence, no subgroup ana-
lysis was possible. Thirdly, the volumes of the conduct-
ing centers of the present study were not enough to
draw definitive conclusions rather than hypothesis gen-
eration. Hence, large scaled randomized and prospective
trials are needed to access safety, efficacy and cost-
effectivity of topical TXA in CIED procedures.
Conclusion
The present study demonstrated for the first time that
addition of topical TXA during CIED implantation was
associated with reduced PH and MBC in patients with
high bleeding risk. However, further trials needed to test
safety and efficacy of topical TXA application in CIED
procedures.
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